ReShape touts efficacy, safety of weight loss products in multi-study presentations

This article was originally published here

ReShape Lifesciences

ReShape Lifesciences (NSDQ:RSLS), formerly known as EnteroMedics, this week presented data from three of its technologies designed to treat obesity and metabolic diseases, touting the safety and efficacy of its products.

Data on the San Clemente, Calif.-based company’s three technologies was presented at the ObesityWeek 2017 conference in Washington D.C. this week.

“Obesity has become a global epidemic that involves significant health issues, comorbidities, and high associated costs to the healthcare system. New, minimally invasive treatment options that are anatomy friendly and help patients manage their disease are required, as existing options are not adequately addressing the concerns of patients and physicians.  We believe the data presented at ObesityWeek 2017 continues to demonstrate the compelling and differentiated benefits of all three of our technologies and validates the use of our devices as effective treatments for obesity,” prez & CEO Dan Gladney said in a press release.

ReShape presented data from a 342-patient study of its ReShape integrated dual balloon designed to treat obesity, touting a mean weight loss of 24.3 lbs for 240 patients with 120 days or more of treatment. That accounts for 10.5% of patient’s initial body weight, and 36.2% of excess weight loss, the company said.

A total of 81% of patients lost 5% of more of their initial body weight, the company said, with 49% losing more than 10% of their initial body weight, with no complications reported during implantations.

In a presentation on its Gastric Vest System, the company reported on results at 12 months in 15 obese patients, finding a mean operative time of 90 minutes with a mean hospital stay time of 24 hours and no intraoperative complications reported.

At one month, all patients reported excess weight loss of greater than 20.1%, with EWL of 85.5% at 12 months. The company also touted that there have been no reports of weight regain amongst Gastric Vest patients to date.

In a poster presention, the company touted results from a 35-patient analysis of vBloc Therapy patients, with an average BMI drop from 41 to 36 and 71% of patients losing over 5% of their initial body weight. Mean initial body weight loss of 12% was reported, with no serious complications.

Late last month, the company announced it was rebranding under the ReShape Lifesciences moniker.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply